- Why counted patient numbers hold up better than estimated ones
- What physician notes show about discontinuation, and how that should shape a target product profile
- How to test a forecast against line of therapy, treatment pathways, payer mix and physician awareness
- How probability of success and trial cost complete the case for a Phase 3 call
Our speakers bring hands-on experience from due diligence, target product profile development and forecasting work. You will leave with three questions to take back to your own assets and a clearer view of the evidence that can answer them.